Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18429026 | 0.93 | GPR119 (0.51) | EPHX1HPGDGPR119RECQL | |
| SCHEMBL5451925 | 0.86 | EPHX1 (0.49) | EPHX1HPGDGPR119MEN1KMT2A | |
| SCHEMBL5457336 | 0.84 | EPHX1 (0.52) | EPHX1HPGDGPR119RECQLMEN1 | |
| SCHEMBL4644042 | 0.84 | EPHX1 (0.52) | EPHX1HPGDGPR119RECQLMEN1 | |
| SCHEMBL5195466 | 0.83 | EPHX1 (0.46) | EPHX1HPGDGPR119RECQLMEN1 | |
| SCHEMBL7065136 | 0.82 | GPR119 (0.48) | EPHX1HPGDGPR119RECQLMEN1 | |
| SCHEMBL2953243 | 0.81 | EPHX1 (0.58) | EPHX1HPGDGPR119RECQLMEN1 | |
| SCHEMBL28758387 | 0.81 | EPHX1 (0.44) | EPHX1HPGDGPR119RECQLMEN1 | |
| SCHEMBL5195241 | 0.80 | EPHX1 (0.48) | EPHX1HPGDGPR119RECQLMEN1 | |
| SCHEMBL16993349 | 0.80 | GPR119 (0.49) | EPHX1HPGDGPR119RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MC4R, MC5R, TAAR5 | EPHX1 1945/4885HPGD 1226/4885GPR119 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.